Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 11/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.40 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946188 | 0.92 | EPHA2 (0.53) | MKNK1EGFRERBB2EPHA2ERBB3 | |
| SCHEMBL9911571 | 0.84 | EGFR (0.52) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL2948762 | 0.82 | EPHA2 (0.63) | MKNK1EGFRERBB2EPHA2KDR | |
| SCHEMBL2944279 | 0.81 | EPHA2 (0.56) | EGFRERBB2EPHA2ERBB3KDR | |
| SCHEMBL2943768 | 0.81 | EGFR (0.66) | EGFRERBB2ERBB3DUS2 | |
| SCHEMBL2950910 | 0.81 | EGFR (0.63) | EGFRERBB2EPHA2ERBB3 | |
| SCHEMBL2945204 | 0.80 | EGFR (0.57) | EGFRERBB2EPHA2KDR | |
| SCHEMBL2947810 | 0.80 | FYN (0.56) | EGFRERBB2KDR | |
| SCHEMBL2944553 | 0.79 | EGFR (0.60) | EGFRERBB2KDR | |
| SCHEMBL2943778 | 0.79 | EGFR (0.59) | MKNK1EGFRERBB2EPHA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198301-B2 | Quinazoline and quinoline derivatives as irreversibe protein tyrosine kinase inhibitors | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2012-06-12 | — | — | US | disclosed |
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240649-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVES AS IRREVERSIBLE PROTEIN TYROSINE KINASE INHIBITORS | ABL1, MAP3K7, MAP3K5 | MKNK1 156/4885EGFR 621/4885ERBB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.